Health Economics›Small cell lung cancer›Relapsed or refractory disease second-line

Relapsed or refractory disease second-line

Small cell lung cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Etoposide (CE) Variant #10	—	R 2 265	21d	4.7 mo	—	7	R 15 853 PFS proxy	1
Cisplatin, Etoposide, Irinotecan Variant #01	—	R 1 455	14d	—	18.2 mo	—	—	1
Lurbinectedin monotherapy Variant #01 Partial	—	—	21d	—	8.3 mo	—	—	—
Amrubicin monotherapy Variant #01 Partial	—	—	21d	—	8.3 mo	—	—	2
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	7.5 mo	—	—	1

5 of 5 regimens shown